Cantero-Nieto Lucia, Álvarez-Cienfuegos Antonio, García-Gómez Jose Alberto, Ríos-Fernández Raquel, Robledo Gema, Ortego-Centeno Norberto
Department of Emergency, Hospital Santa Ana, Granada, Spain.
Department of Rheumatology, Hospital Vega-Baja, Alicante, Spain.
J Clin Densitom. 2021 Jul-Sep;24(3):362-368. doi: 10.1016/j.jocd.2020.05.010. Epub 2020 Jun 2.
INTRODUCTION/BACKGROUND: The purpose of this study was to evaluate the association between Fracture Risk Assessment Tool (FRAX) and serum fibroblast grow factor-23 (FGF-23) levels in SSc women patients compared with healthy controls.
This cross-sectional study was performed in San Cecilio Hospital, Granada (Spain) from November 2017 to May 2019. Sixty-two women with SSc and 62 age and sex matched healthy controls were included in this study. FGF-23 serum concentration was evaluated by indirect enzyme-linked immunosorbent assay. The FRAX scoring tool was applied using the on-line calculator (www.shef.ac.uk/FRAX).
Even though there was no significant difference in FGF-23 levels between SSc women patients and healthy controls (78.2 ± 60.5 vs 80.3 ± 56.3 pg/mL, p = 0.662). FGF-23 levels were positively associated with FRAX index within the study group.
This study shows that FGF-23 status is associated with FRAX index in women with SSc. FGF-23 could be a promising biomarker for detecting risk fracture in SSc women patients.
引言/背景：本研究的目的是评估系统性硬化症（SSc）女性患者中骨折风险评估工具（FRAX）与血清成纤维细胞生长因子23（FGF-23）水平之间的关联，并与健康对照进行比较。
本横断面研究于2017年11月至2019年5月在西班牙格拉纳达的圣塞西利奥医院进行。本研究纳入了62名患有系统性硬化症的女性和62名年龄及性别匹配的健康对照。通过间接酶联免疫吸附测定法评估FGF-23血清浓度。使用在线计算器（www.shef.ac.uk/FRAX）应用FRAX评分工具。
尽管系统性硬化症女性患者与健康对照之间的FGF-23水平无显著差异（78.2±60.5 vs 80.3±56.3 pg/mL，p = 0.662）。在研究组中，FGF-23水平与FRAX指数呈正相关。
本研究表明，系统性硬化症女性患者的FGF-23状态与FRAX指数相关。FGF-23可能是检测系统性硬化症女性患者骨折风险的一个有前景的生物标志物。
